

UPDATE ④ ON OPINABILITY AREAS IN NEUROLOGY - 2026

May 20, 2026 · Palazzo Alabardieri, Naples

ID Provider: 6331

N. ore formative: 7,45

Rivolto a n. 100 FARMACISTA (FARMACISTA PUBBLICO DEL SSN; FARMACISTA OSPEDALIERO); MEDICO CHIRURGO (MEDICINA E CHIRURGIA DI ACCETTAZIONE E DI URGENZA; MEDICINA INTERNA; NEUROLOGIA; PSICHIATRIA; REUMATOLOGIA; NEUROFISIOPATOLOGIA);

Scientific Chairs · Stefania Miniello · Vincenzo Andreone

Committee: M. Napolitano, S. Salvatore, C. Maurea, W. Di Iorio, K. Longo, A. Ranieri, A. De Mase, P. Candelaresi, R. Renna, A. Di Pietro, L. Lombardi, A. Sagnelli, E. Di Battista, C. Cuccurullo, C. Capezzuto, F. Barra, A. De Martino, G. Piccirillo, G. Martusciello, G. De Joanna, A. Stornaiuolo, F. Bonifacio

08.00 Participant registration

Greetings of the Authorities and Opening the Congress - A. D'Amore, M. Mensorio, G. Volpe, V. Giordano

09.00 Introduction and welcome remarks - V. Andreone, S. Miniello

🌟 SESSION 1 · STROKE & MIGRAINE

@ 09:15 – 11:15

Chairs · R. Renna · G. Tedeschi · M. Idone

@ 09:15 – 09:35

Has tenecteplase turned thrombolysis into a decision-shaping therapy, redefining when to transfer, when to observe, and where to treat stroke patients?

E. Spina

Tenecteplase Stroke Pathways Decision Making

@ 09:35 – 09:55

Does the current definition of rescue therapy still hold? Which interventions can truly be considered rescue strategies in contemporary stroke care?

A. Di Pietro

Acute Revascularization Rescue Therapy Post-Thrombectomy

@ 09:55 – 10:15

Overtreatment in acute stroke: which patient profiles and imaging patterns truly justify intervention, and which expose patients to unnecessary risk?

P. Candelaresi

Overtreatment Patient Selection Imaging-Driven Decisions

@ 10:15 – 10:35

Insight the trigeminocervical network: can greater occipital nerve block improve acute management in the emergency department?

A. Stornaiuolo

Migraine in ED GON Block Trigemino-cervical Network

@ 10:35 – 10:55

Why wait? Anti-CGRP therapies and gepants as first-line treatment in migraine: evidence, risks, ideal candidates—and the pharmacoeconomic trade-off.

A. Russo

Migraine Treatment CGRP Health Economics

@ 10:55 – 11:15

General Discussion



Coffee Break · 11:15 – 11:30



KEYNOTE LECTURE

@ 11:30 – 12:00

Molecular Profiling of Brain Gliomas and Its Impact on Therapeutic Strategies

Marc Sanson

(Hôpital La Pitié-Salpêtrière, Paris)

Introduced by M. Napolitano

Neuro-Oncology Molecular Profiling Precision Medicine

SESSION 2 · NEURODEGENERATION & MOOD DISORDERS

12:00 – 14:00

Chairs · P. Barone · M. Idone · L. Sinisi · A. Tessitore

@ 12:00 – 12:20

Biomarkers or clinical benefit: what should truly guide the use of anti-amyloid therapies in atypical or slowly progressive early Alzheimer's disease?

S. Esposito

Alzheimer's Disease Biomarkers Clinical Benefit

@ 12:20 – 12:40

Does pre-pre-symptomatic medicine represent preventive progress—or premature medicalization without robust evidence of benefit?

Intervista a P. Barone

Ethics in Neurology **Overdiagnosis** **Preclinical Disease**

@ 12:40 – 13:00

In mid-stage Parkinson’s disease, what should come first: extended pharmacological optimization or earlier transition to device-aided therapies?

W. Di Iorio

Parkinson’s Disease **Device-Aided Therapy** **Treatment Timing**

@ 13:00 – 13:20

Long-term use of antidepressants: do they alter brain function over time?

A. Iavarone

Mood Disorders **Neuroplasticity** **Long-Term Treatment**

@ 13:20 – 13:40

Essential Tremor, Plus, or Something Else? Rethinking boundaries in tremor disorders.

R. Erro

Movement Disorders **Phenotyping** **Diagnostic Boundaries**

@ 13:40 – 14:00

General Discussion

🕒 Lunch Break · 14:00 – 15:00

🔊 SESSION 3 · NEUROIMMUNOLOGY & EPILEPSY

15:00 – 17:00

Chairs · S. Bonavita · B. Ronga · R. Lanzillo · M. Sannino

@ 15:00 – 15:20

De-escalation in NMOSD: when is it clinically appropriate—and when does it become an economically driven compromise?

A. De Martino

NMOSD **De-escalation** **Clinical Ethics**

@ 15:20 – 15:40

In patients with multiple sclerosis and coexisting autoimmune diseases, is a dual-target immunomodulatory strategy feasible and safe?

R. Lanzillo

Multiple Sclerosis Autoimmune Comorbidity Combination Therapy

@ 15:40 – 16:00

Rethinking “last-line therapy” in drug resistant epilepsy: beyond antiseizure medications.

R. Renna

Drug-Resistant Epilepsy Neurostimulation Novel Strategies

@ 16:00 – 16:20

Is long-term antiseizure medication maintenance after prolonged seizure freedom still evidence-based—or mainly a defensive strategy?

P. Penza

Epilepsy Management ASM Withdrawal Risk Stratification

@ 16:20 – 16:40

Is it really worth treating all CIDP patients chronically?

G. Palumbo

Peripheral Neuropathy CIDP Clinical Decision-Making

@ 16:40-17:00

Hereditary TTR Amyloidosis: management of the per-symptomatic patient, when and how to treat it?

MG Castiglia

Amyloidosis Clinical Decision-Making

SESSION 4 · EVOLUTIONARY NEUROLOGY

@ 17:00 – 17:30

For those who choose to remain

Chair · P. Rinaldi · A. Russo · F. D’Onofrio · B. Ronga

Evolutionary Neurology Human Brain Clinical Perspectives

 **Highlights of the Day · Poll Results · Conclusive Remarks**

@ 17:30

 **Learning Questionnaire · 17:40 – 18:00**

18:00 *Highlights of the day. Poll results and conclusive remarks*

18:30-18:50 Learning questionnaire

RAZIONALE

Few medical specialties have faced such groundbreaking changes in such a short time, as Neurology did, leaving its hazy and somewhat mystical but nihilistic air, turning into a modern, scientific and often treatable medical area. Moreover, general diagnostic and treatment strategies have often given way their way to tailored approaches. Indeed, thanks to the major changes in the diagnosis and treatment of cerebrovascular diseases, particularly in ischemic stroke, the most common neurological disease, nowadays we can halve stroke-related disability. The advent of monoclonal antibodies dramatically changed the quality of life of people suffering from episode and chronic migraines and is about to revolutionize the treatment of dementias. Multiple sclerosis and neuro-immunological CNS and PNS disorders can now benefit from modern diagnostic criteria and innovative care, significantly modifying the course of the diseases. Moreover, new and more tolerable drugs expanded the treatment options for epilepsy and new frontiers are being explored in the management of advanced Parkinson's disease.

However...

Is it all so clear? Is there enough and robust evidence supporting our everyday clinical decision-making? The aim of this conference is to shed light on many persisting grey areas in Neurology. Experts in specific fields will take turns, giving their point of view, and, whenever possible, trying to solve your doubts in a friendly and captivating discussion.

Provider e Segreteria Organizzativa: ECM Network S.r.l., Centro Direzionale P.zzo Avalon 17° Piano Isola E3 80143 Napoli Tel. 0817879520 INT 223, Email: congressi@ecmnetwork.it